Psychological, lifestyle and social predictors of hepatitis C treatment response: A systematic review

Liver International

Volumn 33, Issue 6, 2013, Pages 894-903

  Sublette, Victoria A ^a   Douglas, Mark W ^b   Mccaffery, Kirsten ^a   George, Jacob ^b   Perry, Kathryn Nicholson ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF WESTERN SYDNEY   (Australia)

Author keywords

HCV treatment; Hepatitis C; Hepatitis C treatment outcomes; Hepatitis C treatment predictors; Systematic review

Indexed keywords

CARBOHYDRATE; FAT; POLYUNSATURATED FATTY ACID;

ALCOHOL CONSUMPTION; ARTICLE; ASIAN; ATTITUDE; CLINICAL ARTICLE; COPING BEHAVIOR; DIET; EXERCISE; HEPATITIS C; HUMAN; INFORMATION RETRIEVAL; LIFESTYLE; MENTAL DISEASE; MORBIDITY; MORTALITY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; PSYCHOTHERAPY; SOCIAL ASPECT; SOCIOECONOMICS; SYSTEMATIC REVIEW; TREATMENT WITHDRAWAL;

ADAPTATION, PSYCHOLOGICAL; ALCOHOL DRINKING; ANTIVIRAL AGENTS; COMORBIDITY; DIET; EXERCISE; HEALTH BEHAVIOR; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEPATITIS C, CHRONIC; HUMANS; LIFE STYLE; MEDICATION ADHERENCE; PATIENT EDUCATION AS TOPIC; RISK FACTORS; SOCIAL BEHAVIOR; TREATMENT OUTCOME;

EID: 84878953601     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12138     Document Type: Article

References (85)

1. World Health Organization. Hepatitis C - An Introduction. WHO; 2011. Available at http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index1.html. Accessed 2 December 2011.
2. Heathcote J, Main J. Treatment of hepatitis C. J Viral Hepatitis 2005; 12: 223-35.
3. Hwang EW, Thomas IC, Cheung R, Backus LI. Implications of rapid virological response in hepatitis C therapy in the US veteran population. Aliment Pharmacol Ther 2012; 35: 105-15.
4. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008; 49: 634-51.
5. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
6. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
7. Evon DM, Golin CE, Fried MW, Keefe FJ. Chronic hepatitis C and antivirual treatment regimens: where can psychology contribute? J Consult Clin Psychol 2013; 81: 361-74.
8. Andersen BL, Farrar WB, Golden-Kreutz DM, et al. Psychological, behavioral, and immune changes after a psychological intervention: a clinical trial. J Clin Oncol 2004; 22: 3570-80.
9. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.
10. Vermeiere E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 2001; 26: 331-42.
11. Loguercio C, Federico A, Masarone M, et al. The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis. Am J Gastroenterol 2008; 103: 3159-66.
12. Gapinski MA, Zucker DM. Factors influencing the development of a hepatitis C exercise protocol: a literature review. Gastroenterol Nurs 2005; 28: (Suppl 9) S10-18.
13. Ahmed WU, Arif A, Qureshi H, et al. Factors influencing the response of interferon therapy in chronic hepatitis C patients. J Coll Physicians Surg Pak 2011; 21: 69-73.
14. St. George A, Bauman A, Johnston A, et al. Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. Hepatology 2009; 24: 399-407.
15. Goodwin CL, Forman EM, Herbert JD, Butryn ML, Ledley GS. A pilot study examining the initial effectiveness of a brief acceptance-based behavior therapy for modifying diet and physical activity among cardiac patients. Behav Modif 2012; 36: 199-217.
16. Prus SG. Comparing social determinants of self-rated health across the United States and Canada. Soc Sci Med 2011; 73: 50-9.
17. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
18. Rowan PJ, Tabasi S, Abdul-latif M, Kunik ME, El-Serag HB. Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C. J Clin Gastroenterol 2004; 38: 530-4.
19. John-Baptiste AA, Tomlinson G, Hsu PC, et al. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol 2009; 104: 2439-48.
20. Pellicelli AM, Barbaro G, Barbarini G, Soccorsi F. Management of chronic hepatitis in drug addicts: a systematic review. Clin Ter 2008; 159: 41-9.
21. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
22. Gane E, Pockros PJ, Farci P, et al. Age and sustained virological response in patients with persistently 'normal' alt and chronic hepatitis C treated with peginterferon alpha-2a (40 kDa) plus ribavirin. J Hepatol 2005; (Suppl 2) 205.
23. Aziz H, Athar MA, Murtaza S, et al. Predictors of response to antiviral therapy in patients with chronic hepatitis C from Pakistani population. Chin Med J 2011; 124 1333-7.
24. Iwasaki Y, Ikeda H, Araki Y, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006; 43: 54-63.
25. Villa E, Karampatou A, Camm C, et al. Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. Gastroenterology 2011; 140: 818-29.
26. Zanini B, Lanzini A. Antiviral treatment for chronic hepatitis C in illicit drug users: a systematic review. Antivir Ther 2009; 14: 467-79.
27. Effective Public Health Practice Project (EPHPP). Quality Assessment Tool for Quantitative Studies. Effective Public Health Practice Project (EPHPP); 2010. Available at http://www.ephpp.ca/PDF/Quality%20Assessment%20Tool_2010_2.pdf. Accessed 2010 August 2010.
28. Alvarez-Uria G, Day JN, Nasir AJ, Russell SK, Vilar FJ. Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection. Liver Int 2009; 29: 1051-5.
29. Evon DM, Ramcharran D, Belle SH, et al. Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: Results of the virahep-C study. Am J Gastroenterol 2009; 104: 2949-58.
30. Evon DM, Verma A, Dougherty KA, et al. High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. Dig Dis Sci 2007; 52: 3251-8.
31. Hauser P, Morasco BJ, Linke A, et al. Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder. Psychosomatics 2009; 50: 500-5.
32. Huckans M, Mitchell A, Ruimy S, Loftis J, Hauser P. Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia. Schizophr Bull 2010; 36: 165-72.
33. Lang J-P, Melin P, Ouzan D, et al. Pegylated interferon-alpha2b plus ribavirin therapy in patients with hepatitis C and psychiatric disorders: results of a cohort study. Antivir Ther 2010; 15: 599-606.
34. Leutscher PDC, Lagging M, Buhl MR, et al. Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology 2010; 52: 430-5.
35. Liu SS, Schneekloth TD, Talwalkar JA, et al. Impact of depressive symptoms and their treatment on completing antiviral treatment in patients with chronic hepatitis C. J Clin Gastroenterol 2010; 44: e178-85.
36. Mistler LA, Brunette MF, Rosenberg SD, et al. Case report of 3 patients with severe mental illness and chronic hepatitis C virus infection treated with interferon-alpha. Int J Psychiatry Med 2006; 36: 449-55.
37. Rifai MA, Moles JK, Short DD. Hepatitis C treatment eligibility and outcomes among patients with psychiatric illness. Psychiatr Serv 2006; 57: 570-2.
38. Schaefer M, Hinzpeter A, Mohmand A, et al. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology 2007; 46: 991-8.
39. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37: 443-51.
40. Cheung RC, Currie S, Shen H, et al. Chronic hepatitis C in Latinos: natural history, treatment eligibility, acceptance, and outcomes. Am J Gastroenterol 2005; 100: 2186-93.
41. Gaglio PJ, Rodriguez-Torres M, Herring R, et al. Racial differences in response rates to consensus interferon in HCV infected patients naive to previous therapy. J Clin Gastroenterol 2004; 38: 599-604.
42. Giordano C, Druyts EF, Garber G, Cooper C. Evaluation of immigration status, race and language barriers on chronic hepatitis C virus infection management and treatment outcomes. Eur J Gastroenterol Hepatol 2009; 21: 963-8.
43. Hepburn MJ, Hepburn LM, Cantu NS, Lapeer MG, Lawitz EJ. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 2004; 117: 163-8.
44. Missiha S, Heathcote J, Arenovich T, et al. Impact of Asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol 2007; 102: 2181-8.
45. Pattullo V, Heathcote EJ, Wong DKH. Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C. Hep Intl 2010; 4: 723-31.
46. Reddy KR, Hoofnagle JH, Tong MJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus interferon study group. Hepatology 1999; 30: 787-93.
47. Sterling RK, Hofmann CM, Luketic VA, et al. Treatment of chronic hepatitis C virus in the virginia department of corrections: can compliance overcome racial differences to response? Am J Gastroenterol 2004; 99: 866-72.
48. Yan KK, Guirgis M, Dinh T, et al. Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World J Gastroenterol 2008; 14: 3416-20.
49. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470-7.
50. Anand BS, Currie S, Dieperink E, et al. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology 2006; 130: 1607-16.
51. Bruggmann P, Dampz M, Gerlach T, Kravecz L, Falcato L. Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the swiss hepatitis C cohort study. Drug Alcohol Depend 2010; 110: 167-71.
52. Chang A, Skole K, Gautam M, et al. The impact of past alcohol use on treatment response rates in patients with chronic hepatitis C. Aliment Pharmacol Ther 2005; 22: 701-6.
53. Hosogaya S, Ozaki Y, Enomoto N, Akahane Y. Analysis of prognostic factors in therapeutic responses to interferon in patients with chronic hepatitis C. Transl Res 2006; 148: 79-86.
54. Mochida S, Ohnishi K, Matsuo S, Kakihara K, Fujiwara K. Effect of alcohol intake on the efficacy of interferon therapy in patients with chronic hepatitis C as evaluated by multivariate logistic regression analysis. Alcohol Clin Exp Res 1996; 20: (Suppl 9) 371A-7A.
55. Ohnishi K, Matsuo S, Matsutani K, et al. Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol 1996; 91: 1374-9.
56. Okazaki T, Yoshihara H, Suzuki K, et al. Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers. Scand J Gastroenterol 1994; 29: 1039-43.
57. Tabone M, Sidoli L, Laudi C, et al. Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy. J Viral Hepatitis 2002; 9: 288-94.
58. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-44.
59. Vitaglione P, Fogliano V, Stingo S, et al. Development of a tomato-based food for special medical purposes as therapy adjuvant for patients with HCV infection. Eur J Clin Nutr 2007; 61: 906-15.
60. Negro F, Clement S. Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C. J Viral Hepatitis 2009; 16: 681-8.
61. Jones LW, Demark-Wahnefried W. Diet, exercise, and complementary therapies after primary treatment for cancer. Lancet Oncol 2006; 7: 1017-26.
62. Harding R, Liu L, Catalan J, Sherr L. What is the evidence for effectiveness of interventions to enhance coping among people living with HIV disease? A systematic review. Psychol Health Med 2011; 16: 564-87.
63. Hadziyannis SJ, Sette H, Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346.
64. Zickmund S, Hillis SL, Barnett MJ, Ippolito L, LaBrecque DR. Hepatitis C virus-infected patients report communication problems with physicians. Hepatology 2004; 39: 999-1007.
65. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
66. Myers RP, Patel K, Pianko S, Poynard T, McHutchison JG. The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C. J Viral Hepatitis 2003; 10: 16-22.
67. Sabourin BC, Hilchey CA, Lefaivre M-J, Watt MC, Stewart SH. Why do they exercise less? Barriers to exercise in high-anxiety-sensitive women Cogn Behav Ther 2011; 40: 206-15.
68. Gibala MJ, Little JP, MacDonald MJ, Hawley JA. Physiological adaptations to low-volume, high-intensity interval training in health and disease. J Physiol 2012; 590: 1077-84.
69. McKenna O, Blake C. Management of hepatitis C: the potential benefits of exercise. Phys Ther Rev 2007; 12: 271-6.
70. Payen JL, Pillard F, Mascarell V, et al. Is physical activity possible and beneficial for patients with hepatitis C receiving pegylated interferon and ribavirin therapy? Gastroen Clin Biol 2009; 33: 8-14.
71. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 2003; 125: 1695-704.
72. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-41.
73. Malin SK, Gerber R, Chipkin SR, Braun B. Independent and combined effects of exercise training and metformin on insulin sensitivity in individuals with prediabetes. Diabetes Care 2012; 35: 131-6.
74. Hansen E, Landstad BJ, Gundersen KT, Torjesen PA, Svebak S. Insulin sensitivity after maximal and endurance resistance training. J Strength Cond Res 2012; 26: 327-34.
75. Webster G, Barnes E, Brown D, Dusheiko G. HCV genotypes-role in pathogenesis of disease and response to therapy. Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 229-40.
76. Ohmiya M, Hayashi J, Ueno K, et al. Effectiveness of interferon treatment for patients with chronic hepatitis C virus infection and normal aminotransferase levels. Dig Dis Sci 2000; 45: 1953-8.
77. Aghemo A, Rumi MG, Colombo M. Pegylated interferons α2a and α2b in the treatment of chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2010; 7: 485-94.
78. Rumi MG, Aghemo A, Prati GM, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010; 138: 108-15.
79. Ascione A, De LM, Tartaglione MT, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010; 138: 116-22.
80. Awad T, Thorlund K, Hauser G, et al. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology 2010; 51: 1176-84.
81. Zeuzem S. Do differences in pegylation of interferon alfa matter? Gastroenterology 2010; 138: 34-6.
82. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon Alfa-2b or Alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-93.
83. Knauper B, Turner PA. Measuring health: improving the validity of health assessments. Qual Life Res 2003; 12: (Suppl. 1) 81-9.
84. Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature 2005; 436: 933-8.
85. Forde KA, Reddy KR. Hormones: a potential explanation for differences in response rates to therapy for chronic hepatitis C infection. Gastroenterology 2011; 140: 776-9.